Allt inom mfn_news

Nanexa Receives Approval for Late Breaking Abstract at ADA Congress in Chicago in June

Nanexa announces that the results from the recently completed Phase I-study with NEX-22 have been approved as a Late Breaking Abstract at the prestigious ADA Congress (American Diabetes Association) held in Chicago June 20-23.

Nanexa publishes interim report for January-March 2025

Very interesting data from the latest study and successful share issue.